Bromocriptine-induced pregnancies in women with large prolactinomas.
Fourteen women with large prolactinomas experienced a total of nineteen bromocriptine-induced term pregnancies. None of the women had received prior pituitary tumour therapy. Post-partum sellar X-ray examinations showed signs of tumour enlargement in two women. Only one of them had clinical symptoms of tumour expansion with visual field defects during the pregnancy. The visual impairment improved when bromocriptine treatment was reinstituted and the pregnancy continued to term. The other twelve women had a total of seventeen uneventful pregnancies without symptoms or signs of pituitary tumour expansion. Thus, medical therapy with dopamine receptor agonists is the primary treatment for most infertile women with prolactinomas. The risk of serious pregnancy-induced tumour expansion is very small in properly investigated and carefully supervised patients with large PRL-secreting pituitary adenomas.
D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000150:complications / Q000188:drug therapy*; D010911:Pituitary Neoplasms / Q000150:complications / Q000378:metabolism*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism*
D001971:Bromocriptine; D011388:Prolactin